1. Idorsia Pharmaceuticals. Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg [media release]. http://idorsia.com. 20 Jan 2022.
2. Idorsia Pharmaceuticals. PIVLAZ (clazosentan) IV infusion liquid 150mg [Japanese prescribing information]. 2022. https://www.pmda.go.jp. Accessed 25 Feb 2022.
3. Johnson & Johnson. Johnson & Johnson completes acquisition of Actelion [media release]. http://www.janssen.com. 16 Jun 2017.
4. Axovan. AXOVAN AG announces positive results of phase II trial for clazosentan in vasospasm following subarachnoid hemorrhage [media release]. 12 Aug 2003.
5. Actelion. Actelion announces 9-month results for 2003 [media release]. http://www.actelion.com. 28 Oct 2003.